Artykuł w czasopiśmie
Brak miniatury
Licencja

CC-BY-NC-SACC-BY-NC-SA - Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach

Selected ALKBH dioxygenases are overexpressed in salivary gland tumours

Autor
Marcinkowski, Michał
Grzesiuk, Elżbieta
Kukwa, Wojciech
Pilžys, Tomaš
Garbicz, Damian
Data publikacji
2022
Abstrakt (EN)

Salivary gland tumours (SGTs) are a heterogeneous group of benign tumours of various origins and pathologies, showing a number of DNA modifications. Previously, in malignant head and neck cancer (HNSCC), we found overexpression of ALKBH proteins, the homologs of Escherichia coli AlkB 2-oxoglutarate and Fe(II) dependent dioxygenase. Moreover, we proved the connection of some of these dioxygenases with cancer development. Here, we studied the expression of five of these ALKBH dioxygenases: 1, 3, 4, 5, and FTO in benign SGTs. Using Western blot analysis, we found overexpression of three proteins: ALKBH1, 4, and FTO in SGT as compared to the surrounding, unaffected tissue. ALKBH4 was overexpressed in 76% of patient samples, whereas ALKBH1 and FTO in 65% of the samples. These results differ from those obtained in HNSCC, where FTO overexpression has been observed in 90% of patient samples. We also investigated the relationships between ALKBHs’ expression levels in normal and SGT tissues and identified two correlated pairs: ALKBH1-ALKBH3 and ALKBH1-ALKBH5. Additionally, in tumour tissue ALKBHs: ALKBH1, ALKBH3, ALKBH4, and ALKBH5 levels were correlated with each other. Together, these findings show that the ALKBH proteins exhibit pro cancerogenic action in SGT, even though the levels ALKBHs are generally lower in benign SGT than in malignant HNSCC. We suggest that the overexpression of the ALKBHs, especially FTO, may be used as a cancer marker and for its grading.

Słowa kluczowe EN
salivary gland tumours,
ALKBH proteins,
Western blot
Dyscyplina PBN
nauki biologiczne
Czasopismo
Acta Biochimica Polonica
Tom
69
Zeszyt
4
Strony od-do
889–894
ISSN
0001-527X
Data udostępnienia w otwartym dostępie
2022-12-02
Licencja otwartego dostępu
Uznanie autorstwa- Użycie niekomercyjne- Na tych samych warunkach